The seismic effects of the COVID-19 pandemic have affected not only public health, but society in an unprecedented way. Beyond the continued need for rapid, accurate SARS-CoV-2 diagnostic tests, there is an increasing need for sequencing-based solutions to support epidemiological research investigations into the SARS-CoV-2 genome. Studying genomic variants, what role they play in impactful amino acid changes and using phylogenetic analysis to investigate local regional or national differences is key to understanding its global progression.

This webinar describes the latest QIAseq panel focused on sequencing the SARS-CoV-2 genome. By combining QIAGEN chemistry and analysis solutions into a single targeted workflow, you can unlock high sensitivity, informative results to add deeper insights into your samples. With a flexible protocol, run samples on any Illumina sequencer at varying read lengths to customize your genomic resolution. Learn more about how QIAGEN CLC Genomics Workbench delivers in-depth sequence analyses and comparative genomic analysis. Join this webinar to learn how QIAGEN‘s NGS toolbox can enable your COVID-19 epidemiological research.

About the speaker
Brian Dugan, M.S., Global Product Management, Genomics
QIAGEN
Brian Dugan received his MS from Georgetown University in molecular biology. Previously he has worked in marketing andbusiness development positions for NGS testing, as well as research at Eunice Shriver NICHD. Brian is Associate Directorfor QIAGEN’s UNGS Microbiomics portfolio.
Date of recording:Thursday 4 March 2021
Duration:30 minutes
Categories
Webinar
Next Generation Sequencing
Bioinformatics
Biomedical Research